{"id":451932,"date":"2021-03-05T12:21:32","date_gmt":"2021-03-05T17:21:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451932"},"modified":"2021-03-05T12:21:32","modified_gmt":"2021-03-05T17:21:32","slug":"shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/","title":{"rendered":"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, March  05, 2021  (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of \u00a0Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Immunovant, Inc. investors under the federal securities laws.<\/p>\n<p>To join the class action, go <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EtS7m1PpSArsFl2HCj88VoOr43eyMbur9SAuHH3hAyrjaPUVcxjU7SQ8gmb5Rl8SCwUWm_fhDQ3T220rSsGHQlAJAgQgyF_HUzhR0a_MKQJQr9gy0y5na4Nv3hkRrLve\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QrDSQqgK_993St1-3NDuGD7KD6nqKOol3dwRVh734ITf7OKhHpVAQ2NRm802pui8TUDC8VQayp4Qe2FOG2CAJEbxFxnGW-x8iXZAQfnHe2Y=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@pawarlawgroup.com<\/a>\u00a0for information on the class action.<\/p>\n<p>According to the lawsuit, \u00a0defendants made false and\/or misleading statements and\/or failed to disclose that: Health Sciences Acquisitions Corporation had performed inadequate due diligence into Immunovant Sciences Ltd. prior to the merger, and\/or ignored or failed to disclose safety issues with IMVT-1401; IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating thyroid eye disease (TED) and warm autoimmune hemolytic anemia (WAIHA); the foregoing foreseeably diminished IMVT-1401\u2019s prospects for regulatory approval, commercial viability, and profitability; and as a result, the Company\u2019s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n<p>If you wish to serve as lead plaintiff, you must move the Court no later than <strong>April 20, 2021.<\/strong> A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n<p>No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.<\/p>\n<p>Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.<br \/>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;-<\/p>\n<p>Contact:\u00a0\u00a0<br \/>Vik Pawar, Esq.\u00a0\u00a0<br \/>Pawar Law Group\u00a0\u00a0<br \/>20 Vesey Street, Suite 1410\u00a0\u00a0<br \/>New York, NY 10007\u00a0\u00a0<br \/>Tel: (917) 261-2277\u00a0\u00a0<br \/>Fax: (212) 571-0938\u00a0\u00a0<br \/>info@pawarlawgroup.com\u00a0\u00a0<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3fed4949-c9e8-4609-8b52-bc64eaa8de59\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of \u00a0Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Immunovant, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, \u00a0defendants made false and\/or misleading statements and\/or failed to disclose that: Health Sciences Acquisitions Corporation had performed inadequate due diligence into Immunovant Sciences Ltd. prior to the merger, and\/or ignored or &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451932","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of \u00a0Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Immunovant, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, \u00a0defendants made false and\/or misleading statements and\/or failed to disclose that: Health Sciences Acquisitions Corporation had performed inadequate due diligence into Immunovant Sciences Ltd. prior to the merger, and\/or ignored or &hellip; Continue reading &quot;SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-05T17:21:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW\",\"datePublished\":\"2021-03-05T17:21:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/\"},\"wordCount\":364,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/\",\"name\":\"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=\",\"datePublished\":\"2021-03-05T17:21:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk","og_description":"NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of \u00a0Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Immunovant, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, \u00a0defendants made false and\/or misleading statements and\/or failed to disclose that: Health Sciences Acquisitions Corporation had performed inadequate due diligence into Immunovant Sciences Ltd. prior to the merger, and\/or ignored or &hellip; Continue reading \"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-05T17:21:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW","datePublished":"2021-03-05T17:21:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/"},"wordCount":364,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/","name":"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=","datePublished":"2021-03-05T17:21:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTMzMyM0MDUwODI1IzIwODMxNDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pawar-law-group-announces-a-securities-class-action-lawsuit-against-immunovant-inc-imvt-hsacu-hsac-hsacw\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Immunovant, Inc. \u2013 IMVT, HSACU, HSAC, HSACW"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451932"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451932\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}